$125M RAISE DOUBLES CANCER STARTUP TO A $2B VALUATION

🚨 $125 million in, valuation above $2 billion, and it doubled in under a year.

Thyme Care, the cancer care navigation startup launched in 2020, closed a Series E led by Morgan Health, CNBC reports. Humana and CVS Health Ventures both participated. So did AlleyCorp, HealthQuest Capital and a16z Bio + Health.

The raise roughly doubles the valuation it carried at its Series D less than a year ago.

The business: a virtual navigation platform for cancer patients, built around what co-founder Robin Shah calls "the care in between" — the questions that come up between appointments. It is available to more than 10.5 million people across all 50 states.

📈 The numbers behind the round. Revenue passed $125 million last year, five times the prior year. The company manages more than $7 billion in oncology spend. Shah told CNBC it is now profitable and generating positive free cash flow.

Next move: a new parent entity called Thyme Companies, with Shah as executive chairman after stepping down as CEO in July. Brad Diephuis, previously president and COO, took the top job.

First two targets under the new structure are cancer drug affordability, specifically pushing adoption of lower-cost biosimilars that Shah says have not delivered the promised savings, and clinical trial access, where enrollment problems slow drug development.

Acquisitions are on the table. An IPO, Shah says, is not a near-term view.

Thyme Care ranked No. 18 on the 2026 CNBC Disruptor 50 list.

Would you trust a startup backed by your own insurer to manage your cancer care?

#Thyme Care #healthcare #venturecapital #oncology #causeanuproar